Aurinia制药 AUPH 深 沪
等待开盘 03-26 09:30:00 美东时间
14.37
+0.160
+1.13%
华盛通- 最 高14.84
- 今 开14.53
- 成交量 98.02万股
- 最 低 14.29
- 昨 收 14.21
- 总市值 19.11亿
- 52周最高 16.54
- 市盈率 静 6.94
- 换手率 0.74%
- 52周最低 6.825
- 委 比 37.02%
- 总股本 1.33亿
- 历史最高 33.972
- 量 比 0.68
- 振 幅 3.87%
- 历史最低 1.41
- 每 手 1
- 风险率 3.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning
Aurinia Pharmaceuticals shares are trading higher Monday after announcing a leadership transition seen as a sign of continuity and strategy.
03-23 22:26
Aurinia Pharmaceuticals appoints Kevin Tang as CEO
Aurinia Pharmaceuticals (AUPH) announced on Monday that Kevin Tang, Aurinia’s Chair of the Board, will succeed Peter Greenleaf as chief executive officer. The firm added that Greenleaf will continue a...
03-23 20:22
BRIEF-Aurinia Announces Management Transition
BRIEF-Aurinia Announces Management Transition Aurinia Pharmaceuticals Inc AUPH.O : AURINIA ANNOUNCES MANAGEMENT TRANSITION AURINIA PHARMACEUTICALS INC - APPOINTS KEVIN TANG AS CEO SUCCEEDING PETER GREENLEAF AURINIA PHARMACEUTICALS INC - APPOINTS MICHAEL HEARNE AS CFO Source text: ID:nBw2qBQjSa Furth
03-23 20:08
Earnings Breakdown: Aurinia Pharmaceuticals Q4
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported its Q4 earnings results on Thurs...
02-26 21:56
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Earnings Preview: Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (NASDAQ:AUPH) is preparing to release its quarterly ear...
02-26 02:02
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标
杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。该行指出，2026年生物科技领域将迎来多项关键临...
2025-12-24 17:33
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform, Raises Price Target to $16
Leerink Partners analyst Joseph Schwartz downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Market Perform and raises the price target from $15 to $16.
2025-12-03 21:33
